<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01240161</url>
  </required_header>
  <id_info>
    <org_study_id>2008P000554</org_study_id>
    <nct_id>NCT01240161</nct_id>
  </id_info>
  <brief_title>Personalized Translational Platform for Biomarker Discovery in Brain Tumors</brief_title>
  <official_title>Personalized Translational Platform for Biomarker Discovery in Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Nuclear Medicine and Molecular Imaging</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Electric</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue)
      biomarkers will better predict early brain tumor response to treatments and will be more
      reliable prognostic markers in patients with malignant brain tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>High Grade Glioma</condition>
  <arm_group>
    <arm_group_label>Patients with high grade gliomas</arm_group_label>
    <description>All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT</intervention_name>
    <description>Each patient will have 0-3 or more FLT-PET brain scans.</description>
    <arm_group_label>Patients with high grade gliomas</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to BWH/DFCI emergency department (ED), inpatient, or neurology/
        neurosurgery/ radiation oncology clinics with newly diagnosed brain masses (suspected high
        grade gliomas) will be consented and enrolled in this study after adequate explanation of
        the risks and benefits of the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed or suspected high grade glioma  ≥ 1cm in diameter on postoperative
             anatomic imaging (contrast MRI), prior to initiation of chemoXRT

          -  Anticipated survival ≥6 months

          -  Able to give informed consent

          -  Capable of undergoing MRI and PET scans without the need for sedation or general
             anesthesia

          -  Male or Female

        Exclusion Criteria:

          -  Prior radiation therapy and chemotherapy to the brain

          -  Active intracranial infection or nonglial brain mass.

          -  Recent large intracranial hemorrhage (&lt;1 month)

          -  Expected survival &lt;6 months

          -  Pregnant or nursing

          -  Renal failure

          -  Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging
             visits.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura L Horky, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura L Horky, MD, PhD</last_name>
    <phone>617-732-8667</phone>
    <email>lhorky@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Masha Gaber, BS</last_name>
    <phone>617 582-4755</phone>
    <email>mgaber@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santosh Kesari, MD</last_name>
      <email>skesari@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bradley Brown</last_name>
      <email>bdbrown@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Santosh Kesari, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl K Hoh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura L Horky, MD, PhD</last_name>
      <phone>617-732-8667</phone>
      <email>lhorky@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 20, 2012</lastchanged_date>
  <firstreceived_date>November 10, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Laura L. Horky</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma multiforme</keyword>
  <keyword>FLT</keyword>
  <keyword>PET</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
